Business Operation · 2024
In this section24 topics
- Corporate Information4 items
- Dividend Policy2 items
- Major Shareholders1 item
- Business Strategies Overview6 items
- Material Changes & Developments2 items
- Use of Proceeds from Securities Offerings2 items
- Commitments Made in the Registration Statement2 items
- Group Operating-Structure Policy1 item
- Companies Where the Company Holds ≥10%1 item
- Shareholders with Potential Conflict of Interest2 items
- Relationships Among Major Shareholders1 item
- Shareholders' Agreement2 items
- Shareholding Diagram (Group Structure)1 item
- Income Structure3 items
- Product / Service Characteristics3 items
- Research & Development6 items
- Assets Used in the Business7 items
- Marketing Policy & Competition3 items
- Procurement of Products & Services8 items
- Nature of Business — Overview1 item
- Product Information — Overview1 item
- Projects Under Construction2 items
- Debentures & Bills of Exchange1 item
- Convertible Securities1 item
Corporate Information
Company Name
RATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITED
Telephone
0-4333-3555
Website
http://www.rph.co.th
info@rph.co.th
Dividend Policy
Dividend Policy
The Company has the policy of dividend payout at the rate of not less than 40% of its net profit after tax and legal reserves and other reserves (if any) according to the separate financial statements.
However, such dividend payout may be changed depending on operating results, financial position, liquidity, necessity to use working capital in business operations, investment plan and business expansion plan in the future, market conditions, appropriateness and other factors relating to operations and management of the Company.
Historical Dividend Payments
| This Year | Last Year | 2 Years Ago | 3 Years Ago | 4 Years Ago | Metric | Description | Remark |
|---|---|---|---|---|---|---|---|
| 0.32 | 0.34 | 0.52 | 0.74 | 0.17 | Net profit per share (Baht : Share) | Net profit per share (baht : share) | |
| 0.29 | 0.3 | 0.35 | 0.3 | 0.13 | Dividend per share (Baht : Share) | Dividend per share (baht : share) | 1) The Board of Directors' Meeting No. 3/2024 resolved to approve the interim dividend payment from the operating results for the first 6 months (January 1 - June 30, 2024) of 2024 in the amount of THB 0.11 per share, which was paid on September 9, 2024.
2) The Board of Directors' Meeting No. 1/2025, held on February 15, 2025, resolved to propose to the Annual General Meeting of Shareholders to consider and approve the dividend payment from the operating results for the second 6 months (July 1 - December 31, 2024) of 2024 in the amount of THB 0.18 per share.
Therefore, the Company will pay a cash dividend to shareholders from the operating results for 2024 in the amount of THB 0.29 per share.
However, the dividend payment is still uncertain and must be approved by the Annual General Meeting of Shareholders in 2025. |
| 0 | 0 | 0 | 0 | 0 | Dividend stock ratio (Number of original shares: dividend shares) | Ratio of stock dividend payment (existing share : stock dividend) | |
| 0 | 0 | 0 | 0 | 0 | Dividend share value per share (Baht : Share) | Value of stock dividend per share (baht : share) | |
| 0.29 | 0.3 | 0.35 | 0.3 | 0.13 | Total dividend payment value (Baht : Share) | Total dividend payment (baht : share) | |
| 91.57 | 88.79 | 66.71 | 40.65 | 75.64 | Dividend payout ratio to net profit (%) | Dividend payout ratio compared to net profit (%) |
Business Strategies Overview
Chairman's Message
Year 2024 is the 30 anniversary of Ratchaphruek Hospital Public Company Limited since the establishment and Operation of hospital services.
Previously, the Company has laid the groundwork for the business operation and the core business strategy for better management efficiency. The Company also gave precedence to the corporate governance, placed the risk management guideline for flexibility in encountering any crisis and in recovering from the unaccomplished goals, and built the internal strength before moving forward to the business expansion. All are challenging and important for our stable growth in the future.
Next, the Company will be determined to operate the business in accordance with the vision and main strategy established to give good returns to the shareholders and all groups of stakeholders. Definitely, the Company will continue operating the business with corporate responsibility to local communities, society, and environment to lead the organization to achieve sustainability under main goals in caring for and strengthening the community and the society, and offering opportunities and equality in the society through various activities to support athletes with disabilities, communities, and aged people.
On behalf of the Board of Directors of the Company, I would like to extend my gratitude to all shareholders, joint venture partners, suppliers, business partners, financial institutions, customers, and other related parties who have strongly supported and trusted the Company throughout 31 years.
We greatly appreciate our executives and employees who have made a valuable contribution and effort to drive the Company to meet goals and success.
(Mr.Sudhon Sriyapant)
Chairman of the Board
Vision
"We are determined to be the leading private hospital that provide international high-quality standard and humanized care"
Objectives
1. The company's business operations will prioritize the quality and safety of patients and service recipients, emphasizing holistic patient care with a heart of humanity.
2. Aiming to be a Beyond Hospital for Khon Kaen residents and the public.
3. Creating quality service standards and focusing on individuals as the person centered care.
Goals
The Company was committed to becoming the leading private hospital in Khon Kaen in terms of medical services and patient care. It also aimed to enhance its medical capabilities to establish itself as a top-tier hospital in Northeastern Thailand. The key objectives included:
Surgery Hospital (Subsidiary) In 2024,
the Company signed a contract with Community Architects and Environmental Design Arsomsilp Co., Ltd. to provide architectural design services for the renovation of an existing hospital into a cosmetic surgery hospital, maintaining the principles of a healing environment.
As of Q4 2024, the process of selecting and bidding for a primary construction contractor was underway. Initially planned as a renovation project, the Company, in collaboration with architects and engineers, decided to reconstruct the entire project after considering various factors. The selection of the contractor and signing of the contract were expected to be completed by January 2025, with construction estimated to take approximately 13 months.
Business Strategies
1. International standard hospitals
There are many private hospitals in the area, which increases competition. Therefore, the hospital focuses on policies to improve the quality of care in every step in order to maintain international quality (JCI), so that people receive quality health services under standards, ethics, and professional ethics.
2. Create an excellent experience for patients and service recipients.
Emphasize the experience that patients and their relatives will receive from using services and medical treatment, as well as all stakeholders. Aim to develop a seamless service process to meet patient expectations.
3. Marketing and corporate Branding
Develop more effective marketing competitive potential, which will help reach more patients and increase brand awareness of Ratchaphruek Hospital.
Other Information
| Name | Description |
|---|---|
| Mission | "We committed to improvement, and provide healthcare with international standard for quality and safety, with empathy, accessible ,a leader in healing environment, focus on excellent patient experiences" |
Material Changes & Developments
Introduction
In 2024, the Company has implemented its strategies by focusing on increasing the quality and safety of medical treatment in every care process, from before treatment, during treatment and after treatment, taking care of patients seamlessly at every step in order to become a leading international hospital and is committed to achieving operating results in line with the Company’s goals, with details as follows:
Material Changes & Developments
| Year | Description |
|---|---|
| 2,022 | • Received the 1st renewal of JCI standardsReceived silver award in “Caring Services” • Opened 2 specialist centers. • Memorandum of cooperation for the Social Employment Promotion Project for disabled persons. • Opened MRI (Magnetic Resonance Imaging) service |
| 2,023 | • Awarded a 5-star rating or "Excellent CG Scoring" for 2023 corporate governance. • Received the “Outstanding Business” award in 2023 for being an important part in promoting and supporting the Region 4 Workers’ Rehabilitation Center. • Received Global Healthcare Accreditation (GHA) with Excellence to Ratchaphruek Hospital for Medical Travel Services, a first in the Northeastern region. • Announcement of the establishment of 1 subsidiary company, namely Kaen Phang Nga Company Limited, registered on August 21, 2023. The Company has a registered capital (initial) of 5 million baht, divided into 1 million shares, with a par value of 5 baht per share. |
| 2,024 | • Announcement of the Treasury Stock repurchase project, the maximum amount used for repurchasing shares is not more than 200 million baht, the amount to be repurchased is not more than 35 million shares (not more than 6.41 percent of all shares sold) From December 13, 2024 to June 12, 2025 • RPH has been assessed for the 2024 Corporate Governance Report of Thai Listed Companies (CGR) at the 5-star or “excellent” level (Excellent CG Scoring) for the 2nd consecutive year by the Thai Institute of Directors (IOD) with support from the Stock Exchange of Thailand. The assessment program has been participated by over 808 listed companies. • Received the KKCC AWARD 2024 for outstanding business organizations and individuals for outstanding business organizations and individuals who have contributed to the growth of trade and business in Khon Kaen Province. • Received the award for "Business that creates potential for Khon Kaen City, together with the Khon Kaen Chamber of Commerce". The plaque of honor for RPH as “Outstanding Business” for the year 2024, which has been an important part in promoting and supporting the Rehabilitation Center for Workers in Region 4 for the 2st consecutive year. • Increase the capital of the subsidiary company for the first time x May 2024 by increasing the registered capital by another 10 million baht, resulting in the company having a registered capital of 15 million baht, divided into 3 million shares at 5 baht per share. • Increased the subsidiary's capital for the second time on December 1, 2024 by increasing the registered capital by another 50 million baht, resulting in the company having a registered capital of 65 million baht, divided into 13 million shares at 5 baht per share. |
Use of Proceeds from Securities Offerings
Introduction
In 2024, the Company will not raise additional capital.
Is There Money Raised from a Securities Offering Still to Report On?
No
Commitments Made in the Registration Statement
Introduction
ในปี 2567 บริษัทฯ ไม่มีคำมั่น หรือข้อผูกพันใดหรือเงื่อนไขใด ๆ เพิ่มเติม
Are There Commitments or Conditions from an Offering or Listing?
No
Group Operating-Structure Policy
Description
As of December 31, 2024, the company has 1 subsidiary, Kaen Pha Nga Company Limited,
with registered capital of 65,000,000 baht, 13,000,000 shares. Consisting of 3 directors as follows:
1. Dr. Teerawat Srinakarin, M.D.
2. Professor Dr. vallop Laopaiboon, M.D.
3. Associate Professor Dr. Srichai Krusun, M.D.
List of shareholders, number of shares, percentage of shareholding (%)
Ratchaphruek Hospital Public Company Limited holds 12,999,998 shares, accounting for 99.98 percent.
Dr. Teerawat Srinakarin, M.D., holds 1 shares, proportion 0.01 %
Professor Dr. vallop Laopaiboon, M.D., holds 1 shares, proportion 0.01 %
Totaling 13,000,000 shares or 100%.
Companies Where the Company Holds ≥10%
Companies (≥10% Holding)
| Company Name | Address | Province | Zip Code | Telephone | Business Type | Security Type | Shares | Paid-up Shares |
|---|---|---|---|---|---|---|---|---|
| KAEN PA-NGA COMPANY LIMITED | No. 150/18, Moo 7, Mittraparb Road Nai-Mueang Sub-Distric, Mueang Khon Kane Distric | Khon Kaen | 40000 | 0896223994 | Spacial Hospitals allowed patients to stay overnight | Common shares | 13,000,000 | 13,000,000 |
Income Structure
Product / Service Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue from operations | Total revenue from operations | 1,125,171.34 | 100 | 1,160,586.27 | 100 | 1,326,180.99 | 100 |
| Other revenue from operations | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other | Others | 0 | 0 | 0 | 0 | 0 | 0 |
Export Income
| Category | Description | This Year | This Year % | Last Year | Last Year % | 2 Years Ago | 2 Years Ago % |
|---|---|---|---|---|---|---|---|
| Total revenue | Total revenue | 1,125,171.34 | 100 | 1,160,586.27 | 100 | 1,326,180.99 | 100 |
| Domestic | Domestic | 1,125,171.34 | 100 | 1,160,586.27 | 100 | 1,326,180.99 | 100 |
| International | International | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income
| Operating Other Income | Non-Operating Other Income | Share of Profit |
|---|---|---|
| 1710 · As of year: 24430.21 · Description: Total other income · As of yesteryear: 16941.8 · As of year before yesteryear: 14075.8 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 | 1712 · As of year: 24430.21 · Description: Other income not from operations · As of yesteryear: 16941.8 · As of year before yesteryear: 14075.8 | 1713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 |
Product / Service Characteristics
Introduction
The Company remains committed to operating with resilience, guiding the hospital through an era of transformation and competition. It is confident in maintaining its position as one of the most stable and sustainable hospitals, contributing to the broader society. The Company is dedicated to fulfilling its role as a responsible member of a quality community under the motto: "Whoever you are, we are here to understand and care for you with a human touch."
Business Type
3114
Business Groups
| Business Group | Description |
|---|---|
| Centers of Specialty (COS). | As of the current date, the Company offers medical services that encompass general medical care and increasingly complex specialized treatments. To meet new customer demands, the hospital has expanded its capacity to provide a wider and more comprehensive range of medical services, including the establishment of Centers of Specialty (COS). Comprehensive Breast Center, Hearing and Balance Center, Kidney Center. Maternal and Child CenterS, pecialty Disease Treatment Clinic 1) Beast Center The company provides comprehensive treatment services, including surgeons, radiologists specializing in diagnostic radiology and breast imaging, radiologists specializing in radiation therapy, and internists specializing in chemotherapy. Pathologists work as a team to provide close care and plan individual treatment in accordance with international standards for example, breast conservation treatment is provided for women with early-stage cancer. There are radiologists who provide consultation and treatment that focuses on radiation therapy without having to perform a mastectomy for patients who can undergo breast-conserving treatment. The services of the breast clinic are as follows: • Detailed breast examination by a specialist doctor • Breast examination with a modern digital mammogram and ultrasound • Collection of breast tissue or cyst samples using a small needle to suck out cells for examination • Collection of tissue samples using a needle to cut breast tissue using an ultrasound guide • Collection of tissue samples by surgery In cases where: - The doctor can feel a lump, the lump can be surgically removed immediately if there are no other precautions. If the doctor cannot feel a lump, such as finding a group of calcium deposits that are suspected to be cancerous from a mammogram, the radiologist will place a guide wire at the location of the calcium deposits using a mammogram (Needle Localization) before surgery. 2) Hemodialysis Center The company has standard hemodialysis machines certified by the Kidney Association and high-performance hemodialysis machines (Online hemodiafiltration) to increase the efficiency of waste removal. The services are as follows: • Standard hemodialysis machines for patients with acute renal failure who need urgent hemodialysis. • 24-hour continuous hemodialysis for patients with acute renal failure who are in critical condition and cannot receive standard hemodialysis. • Entertainment equipment such as personal IPADs for patients. • Special guest rooms for relatives at the Hemodialysis Center. • Kidney biopsy services. Kidney biopsy services by experienced specialists. 3) Comprehensive Ear, Hearing and Balance Center The company recognizes the importance of this problem and has established the Ear, Hearing and Balance Center to diagnose, treat and rehabilitate patients comprehensively. Currently, we are the first and only private hospital in the Northeast that has a team of otolaryngologists (Neurotologist), pediatric audiologists (Pediatric Audiologist) and audiologists (Audiologist), as well as modern equipment that can accurately diagnose the causes of ear diseases, hearing loss and balance in children, adults and the elderly, including providing effective treatment and rehabilitation for each patient. The services of the Ear, Hearing and Balance Center are divided into 4 areas as follows: Diagnosis: - Ear infection - Chronic otitis media - Severe otitis media (Cholesteatoma) - Hearing loss - Sudden hearing loss - Tinnitus - Meniere's disease - Benign paroxysmal positional vertigo - Otosclerosis - Ossicular chain disruption Ear canal stenosis Acoustic neuroma • Surgery: - Injection through the tympanic membrane - Perforation of the tympanic membrane to insert drainage tubes from the middle ear - Tympanic membrane grafting - Otosclerotomy for severe otitis media - Middle ear bone repair - Ear canal expansion 4) Maternal and Child Center the company provide a full range of health care service for mothers and children, from planning before you become pregnant to caring for you and your baby after you give birth including restoration of mothers with postpartum counseling on family planning and those with infertility. • We also provides the services of vaccinated against various diseases, discussion about the development of children from birth by Pediatrician teams such as allergists, endocrinologist, Neurologist, etc. • Significantly, we also have professional teams trained to treat a wide range of developmental disorders in children • including autism and any other related conditions. • Furthermore, our doctor team will take care of you throughout before and after give births with innovative medical devices such as Ultrasound, Endoscopic surgery through the vagina, checking the condition of the fetus to the international standard. Importantly, you can participate in Promoting maternal breastfeeding mothers throughout pregnant time without any charges. ServicesChildrenVaccinated against various diseases.Advices about the development of children from birthHeart disease.Kidney disease. Diseases of the urinary tract.MotherDiagnosed by ultrasound.Cesarean.Endoscopic surgery through the vagina.Check the condition of the fetus to the international standard.Training to prepare for birth.Promoting maternal breastfeeding mothers.Clinical treatment of infertility, etc. 5) Specialty Disease Treatment Clinic In addition, the company also provides general and complex disease screening services in many fields with modern technology. The services are provided by specialized doctors and medical personnel who are ready to take care of service recipients with a heart of humanity. |
| Outpatient Services (OPD) | (Out Patient Department: OPD) The company has a total of 36 patient examination rooms and has added a clinic for respiratory system diseases (ARI CLINIC) to provide services for specific patient groups. This clinic is dedicated to patients with symptoms such as fever, cough, sore throat, runny nose, or difficulty breathing. It has been established to help segregate high-risk patients during the COVID-19 pandemic. As 31 December 2024 , the company has 36 patient examination rooms. |
| Inpatient Services (IPD) | The company provides various types of patient rooms to accommodate the needs of patients and their relatives, including Deluxe rooms, Super Deluxe rooms, Junior Suites, Suites, Premier rooms, Intensive Care Unit (ICU) rooms (Normal), Intensive Care Unit (ICU) rooms (positive/negative pressure), Nursery for sick infants, Nursery for newborns, and Delivery Waiting Rooms. The room charges are calculated based on the type of room, and for patients who pay for medical services in cash/credit card and for medical expenses exceeding the insurance coverage, there are discounts available on room charges. As 31 December 2024 , the company has198 Beds for IPD |
| Additional Service Scope | Additional Service Scope 1. Kitchen and Food Center: To ensure the nutritional quality of patients, the Company has outsourced food production to an external provider, with dietitians overseeing and determining appropriate meal plans for patients. Additionally, a food center is available for general visitors, located on the first floor near the entrance by the Phra Phrom Shrine. 2.Emergency Vehicle Service: A 24-hour emergency and critical patient transfer service is available, equipped with advanced, high-efficiency life-saving medical tools and devices, operated by skilled and experienced emergency professionals. 3. International Marketing Department : This department consists of language experts, including those proficient in English, Chinese, and German, to provide accurate hospital information to international patients and ensure an excellent experience for them. Additionally, a team of interpreters is available to assist patients in various languages, facilitating communication, coordination, and travel arrangements for those arriving from or departing to other countries. |
Research & Development
Has R&D Policy (Y/N)
No
Introduction
In 2024, the Company has no research investment plan, but considering the size of the business, responding to the needs of stakeholders and being ready to support economic, social and environmental changes, which lead to increased opportunities and competitiveness.
R&D Cost — Label
Research and development (R&D) expenses over the past 3 years (Million Baht)
R&D Cost — This Year
0.0
R&D Cost — Last Year
0.0
R&D Cost — 2 Years Ago
0.0
Assets Used in the Business
Introduction
The assets used in the business operations of the Company and its subsidiaries, according to the book value as of December 31, 2024, are as follows:
Permanent Assets — Description
The Company divides fixed assets into 3 types: land, buildings and equipment.
Permanent Assets — Appraisal
| Asset | Ownership | Obligation | Appraisal Value | Description |
|---|---|---|---|---|
| Land 9 plots | Ownership | None | 78.84 | Land 9 plots (are 4-3-93.8 rai) Location on Khon Kaen Province |
| Land 2 plots | Ownership | Mortgage | 135.4 | Land 2 plots (are 33-0-39 rai)
Location on Khon Kaen ProvinceThe property is under mortgage.
Which is under bank mortgage |
| Building | Ownership | None | 0.23 | Building with area 7,412 square meters.
Location on Mittraparb Rode, Mueang, Khon Kaen |
| Building (14 floors) | Ownership | Mortgage | 481.09 | Building 14 floors
Total usable area 36,000 square meters.
Location on Mittraparb Rode, Mueang, Khon Kaen |
| Land 4 plots | Ownership | None | 12 | 4 plots of land, total area (5-2-45.7 rai)
Location on Chum Pae, Khon Kaen Province |
Intangible Assets — Description
• Intangible assets of the Company and its subsidiaries
As of December 31, 2024, the Company and its subsidiaries had net intangible assets o 19.44 million Baht, most of which were computer program costs used in the hospital operations and related businesses of the Company and its subsidiaries.
Intangible Assets — Appraisal
| Asset | Type | Type (if Other) | Appraisal Value | Description |
|---|---|---|---|---|
| Company and its subsidiaries had net intangible assets | Software | 19.44 | As of December 31, 2024, the Company and its subsidiaries had net intangible assets 19.44 million Baht, most of which were computer program costs used in the hospital operations and related businesses of the Company and its subsidiaries. | |
| Assets of the Company and its subsidiaries - Leasehold Rights | Others | Property rights-lease contract | 5.18 | Right of Use-Lease
As of December 31, 2024, the net book value of Right of Use-Lease was 5.18 million baht, most of which were medical equipment and tools used in hospital operations. |
Has Subsidiaries Investment Policy (Y/N)
Yes
Subsidiaries Investment Policy — Description
Policy for investment in subsidiary and associated company and policy for management of such companies, including control and governance mechanisms of Ratchaphruek Hospital Public Company Limited
Policy for investment in subsidiary and associated company and policy for management of such companies, including control and governance mechanisms The Company manages its business by upholding Guidelines for Good Corporate Governance prescribed by the Stock Exchange of Thailand (“SET”). In investment decisions, not only considering return to all stakeholders, but also the Company operates its business in line with Guidelines for Good Corporate Governance prescribed by the SET and the Office of the Securities and Exchange Commission (“Office of the SEC”), which is a factor of importance to the Company. The Company realizes that adopting the Guidelines for Good Corporate Governance is a method for control and mechanism which will lead to investment governance and transparent and verifiable management system. This will allow the Company as major shareholder to control, manage and be responsible for the operations, including determination of directions for invest company as if it was a unit of the Company. In addition, the Company will be able to monitor management of such business in order to protect its benefits from investment. Such measures for corporate governance will provide added-values and assurance to stakeholders with regards to continuity and sustainability of the Company’s investment.
The Company, therefore, sets this policy for investment in subsidiary and associated company and policy for management of such companies to be in line with rules regarding governance of operations of subsidiary and associated company pursuant to the Notification of the Capital Market Supervisory Board No. TorChor. 28/2551 Re: Application for and Approval of Offer for Sale of Newly Issued Shares and Guidelines for Good Corporate Governance of the SET, the details of which are as follows:
Policy for investment in subsidiary and associated company
The Company has a policy to invest in subsidiary or associated company which support the Company’s business operations and of which investment would create synergy, generate additional revenue streams, and increase profitability of the Company. The Company will consider proportion of investment, expected profitability, possible risks and financial status of the target companies prior to making investment decision. Any investment decision must obtain a resolution of the Company’s board of directors or shareholders, as the case maybe, approving the transaction. The Company shall appoint qualified representative as director of investee company in order to set key policies and for good corporate governance of subsidiaries and associated company.
1. The Company has set guidelines in exercising rights by its representatives in shareholders’ meeting of subsidiary and associated company to be consistent with the proportion of shareholding in subsidiary and associated company.
This is also for compliance with Guidelines for Good Corporate Governance and maintain maximum benefits to the Company, its subsidiaries and associated companies, and other shareholders.
(1) Certification of minutes of the general meeting of shareholders and extraordinary general meeting of shareholders
- Approve if draft minutes records all details of the meeting completely and accurately.
- Abstain if the Company’s representative did not attend the meeting.
(2) Certification of annual financial statements
- Approve if auditor expresses his/her opinion unconditionally or with condition which is not material to the financial statements and does not have an impact on overall benefits of the shareholders.
- Disapprove if auditor expresses opinion or makes an observation that any part of the financial statements may be incorrect.
(3) Appointment of directors and determination of directors’ remuneration Appointment of directors
- Approve if the person is nominated by resolutions of the Company’s board of directors’ meeting and has qualifications and does not possess any prohibited characteristics as specified under the laws or relevant regulations of the Securities and Exchange Commission. The person nominated shall have knowledge, capabilities, and experience beneficial to the business operations, can devote sufficient time as director of the company, and perform his/her roles and responsibilities as director with attention. The consideration whether any person is suitable to act as director of the company shall be on an individual basis.
- Disapprove if it is a reappointment of existing director and such director lacks any qualification and possesses any prohibited characteristic as specified under the laws or relevant regulations of the Securities and Exchange Commission, or such person lacks knowledge, capabilities and experience beneficial to the business operations, or such person cannot devote sufficient time as director of the company and did not perform his/her roles and responsibilities as director with attention without reasonable causes. The appointment of new director in associated company or subsidiary shall not be contrary to the Company’s rules regarding controlling business specified in Item
2.1 and any other relevant laws. Determination of directors’ remuneration
- Approve if the proposed directors’ remuneration is appropriate for roles, responsibilities and performance of the Board of Directors as reflected through operating results and operating performance and/or financial positions of such subsidiary or associated company.
- Abstain if the proposed remuneration is a special payment of undisclosed amount or ESOP which would generate significant dilution effect to subsidiary or associated company, or is not in compliance with the rules of supervisory agencies and/or is not appropriate for roles, responsibilities and performance of the Board of Directors as reflected through operating results and operating performance and/or financial positions of such subsidiary or associated company.
(4) Appointment of auditor and determination of audit fees
- Approve if after due consideration, the auditor and the audit firm is reliable and able to perform their roles in auditing and reviewing financial statements correctly and express their opinion independently. The audit fees proposed shall be at a level comparable to similar audit firms.
- Abstain if there is any doubt in reliability or independency of the auditor or the audit fees is significantly different from the previous year’s audit fees without reasonable cause.
(5) Appropriation of profits
- Approve As proposed by the board of directors of subsidiary and associated company and consistent with the dividend policy and not contrary to the relevant laws.
- Disapprove if payment of dividends is not in line with financial positions, future plan, and/or any other relevant factors of subsidiary and associated company.
(7) Approval of other matters apart from Items (1) – (6)
- Approve agenda which is beneficial to subsidiary or associated company or to shareholders and with fair and reasonable proposals, and the conduct of business shall be with ethics and in accordance with the relevant laws. The approval process of such matter shall be in accordance with the laws and the Company’s Articles of Association.
- Disapprove if a transaction is not in the ordinary course of business and is being considered without clarifications and reasons and necessity for the entry into the transaction
(8) Approval of any matter which was not specified as one of the agenda items prior to the meeting May disapprove consideration of any other matter which was not specified as one of the agenda items prior to the meeting, particularly matter of significant importance, as there should be considerable time spent on studying important information which is critical to decision-making. Such matter or agenda may be proposed for consideration during the next shareholders’ meeting.
2. The Company determines management structure of subsidiaries and associated companies in order to oversee management and operations of its subsidiaries and associated companies as if they were units of the Company. To look after its investment, the Company shall have the following procedures for monitoring the management of its subsidiaries and associated companies:
2.1 Nomination of its representative as director of subsidiary and associated company
The Company shall nominate its representative, who has been approved by resolution of the Company’s Board of Directors, as director of subsidiary and associated company at the minimum number corresponding to its proportion of shareholding in such subsidiary and associated company.
The nominated person shall have qualifications, roles and responsibilities and shall not have prohibited characteristics as specified under the notifications of the Securities and Exchange Commission and the Stock Exchange of Thailand regarding the lack of trustworthiness of directors and management of the company.
2.2 Roles and responsibilities of director of subsidiary and associated company Person who is nominated by resolution of the Company’s Board of Directors as director of subsidiary and associated company shall have the following roles and responsibilities:
2.2.1 Director of subsidiary and associated company shall have the roles and responsibilities as determined by the board of directors of subsidiary and associated company and/or the shareholders’ meeting of subsidiary and associated company. Director of subsidiary has discretion to consider and vote during the board of directors’ meeting of subsidiary for matters relating to general management and normal business operations of the subsidiary as directors and management of such subsidiary deems appropriate for the utmost benefits of the subsidiary and the Company.
However, consideration and voting of the below matters are considered important matters. The person appointed by resolution of the Board of Directors as director of subsidiary cannot exercise his/her discretion in voting for those matters during the board of directors’ meeting of the Company’s subsidiary. Such person shall obtain a prior consent from the Board of Directors’ meeting or the shareholders’ meeting of the Company (as the case may be).
A. Entry into a transaction with related person of subsidiary pursuant to the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Company Concerning Connected Transactions B.E. 2546 (2003) and the Notification of the Capital Market Supervisory Board No. TorChor. 21/2551 Re: Rules on Connected Transactions (“Connected Transaction Notifications”)
B. Entry into a transaction which is an acquisition or disposal of assets of the subsidiary pursuant to the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Company Concerning Acquisition or Disposal of Assets and the Notification of the Capital Market Supervisory Board No. TorChor. 20/2551 Re: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets (“Acquisition and Disposal of Assets Notifications”).
C. Entry into significant transactions pursuant to Items 2.2.4, 2.2.5 and 2.2.6
2.2.2 Director of subsidiary and associated company must perform his/her duties with responsibilities, care and honesty, and shall comply with the laws, objectives, articles of association of subsidiary or associated company, resolutions of the board of directors’ meeting and the shareholders’ meetings, and policies of the Board of Directors of which the board of directors of subsidiary has approved as per the resolutions of the Board of Directors.
2.2.3 Director of subsidiary has a duty to disclose to the Company complete and accurate information regarding financial status and operating performance, connected transactions, and material acquisition or disposal of assets of subsidiary within the period prescribed by the Company. Acquisition or disposal of any material assets should take the relevant rules and regulations of the Office of the SEC and SET into consideration.
2.2.4 Apart from entry into transactions in accordance with Connected Transaction Notifications or Acquisition and Disposal of Assets Notifications, entry into the following transactions are deemed material. Subsidiary has a duty to present information regarding such type of transaction to the Company for approval by the meeting of the Executive Committee of the Company prior to considering it in its meeting of the board of directors. In addition, director appointed by the Company must obtain approval from the Company’s Board of Directors prior to voting for the following matters:
(1) transfer or waiver of benefits with the value exceeding the authorized limit of the Executive Committee of the Company in approving expenses, including waiver of material rights and claim to those causing damages to subsidiary;
(2) sell or transfer business of subsidiary, whether wholly or material part thereof, to third party;
(3) purchase or acquire business of another company as subsidiary’s own business in the proportion which is considered material;
(4) entry into, amend or terminate agreement relating to lease of business by subsidiary, whether wholly or material part thereof, including authorization of third party to manage business of subsidiary or merger of business with third party with an objective to share profit and loss;
(5) lease or hire-purchase of business or assets of subsidiary, whether wholly or material part thereof;
(6) borrowing, lending, providing credits, guarantees, entry into any juristic which will result in subsidiary carrying significantly increased financial burden due to the third party lacks liquidity or is not able to perform his debt obligations or any other financial supports to any person which is not within the ordinary course of business;
(7) payment of annual dividends and interim dividends (if applicable) of subsidiary;
(8) cessation of subsidiary’s business where the calculation of transaction size of subsidiary’s business which is being ceased compared to size of the Company according to the Acquisition and Disposal of Assets Notifications must fall within the category which requires approval from the Board of Directors of the Company; (9) amendment of articles of association of subsidiary.
2.2.5 The following matters are important matters of which subsidiary requires to obtain prior approval from the Company’s shareholders meeting:
(1) if subsidiary agrees to enter into transaction with its related party or acquire or dispose its assets where the relevant rules of the Capital Market Supervisory Board and the Board of Governors of the Stock Exchange of Thailand shall apply, mutatis mutandis. The transaction size compared to size of the Company calculated according to such rules must result in the transaction size which requires approval from the Company’s shareholders meeting;
(2) capital increase by issuing and allotment of subsidiary’s newly issued shares, including decrease of registered capital which is not proportionate to existing shareholding and would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, by 10% or more of the paid-up capital of subsidiary or would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, to less than 50% of the paid-up capital of such subsidiary;
(3) any other act which would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, by 10% or more of the paid-up capital of subsidiary or would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, to less than 50% of the paid-up capital of such subsidiary;
(4) cessation of subsidiary’s business where the calculation of transaction size of subsidiary’s business which is being ceased compared to size of the Company according to the relevant rules of the Capital Market Supervisory Board and the Board of Governors of the Stock Exchange regarding acquisition or disposal of assets shall apply, mutatis mutandis, and the transaction size calculated according to such rules must fall within the category which requires approval from the Company’s shareholders meeting;
2.2.6 Apart from transactions under Items 2.2.4 and 2.2.5, if subsidiary will enter into any other transaction which is not in its ordinary course of business and/or any transaction which will materially affect itself, such transaction must obtain prior-approval from the Board of Directors of the Company or the Company’s shareholders meeting. The subsidiary shall comply with requirements for the transaction size calculated in accordance with the rules prescribed by the Acquisition and Disposal of Assets Notifications.
3. Directors and management of subsidiary must disclose and deliver information regarding personal of interest, including interest of their related persons, in relation to any transaction or in other business which might raise conflict of interest with the Company, subsidiary, board of directors of subsidiary or person authorized by subsidiary within the period of time as prescribed by subsidiary. Such information shall be used as supporting information for decision making or passing any approval by considering overall benefits of subsidiary and the Company as critical factors. Directors and management of subsidiary shall not participate in the consideration of any matter of which they have personal interest or conflict of interest.
4. Directors and management of subsidiary, including any person related to such directors and management, have the duty to inform to the board of directors of subsidiary relationship and transaction with subsidiary which might raise conflict of interest and avoid entering into transaction which might raise conflict of interest with subsidiary.
The board of directors of subsidiary has the duty to inform such matter to the Company for acknowledgement. The following acts, which result in directors, management or any person related to subsidiary gaining financial benefits other than that ordinarily received or cause damages to subsidiary, are presumed to be material conflict of interest with subsidiary:
(a) any transaction between subsidiary and director, management or any connected person which is not in compliance with rules regarding connected transactions; (b) use of known information of the Company and subsidiary, except information which has been publicly disclosed; or
(c) use of asset or business opportunity of the Company and subsidiary in a way which violates the rules or general practice as prescribed by the Capital Market Supervisory Board.
5. Subsidiary must deliver to the Company information or documents relating to its operations upon appropriate request.
6. If the Company finds any material issue, it may request subsidiary to clarify and/or deliver document as supporting information for its consideration.
7. Directors, management, employees, staff or authorized persons of subsidiary, including their spouse and minor children, are not allowed to use internal information of the Company and subsidiary, whether such information is obtained through performance of duties or through any other method or, whether or not such information has significant impact on the Company and subsidiary, for their own benefits or others, whether directly or indirectly and whether or not for consideration.
8. Directors, management of, or any person related to, subsidiary may enter into a transaction with subsidiary only upon receiving approval from the Board of Directors of the Company or the Company’s shareholders meeting as required based on transaction size calculated pursuant to the rules of the Connected Transaction Notifications. Exceptions apply where transaction is with terms and conditions similar to transaction with other counterparties under the same circumstances, the position as director, management or related person, as the case may be, do not have influence on the transaction, and trade terms and conditions of the transaction have been approved by the Board of Directors of the Company or in line with principles as approved by the Board of Directors.
Marketing Policy & Competition
Reporting Mode
3117
Marketing Policy (Overall)
• Marketing Policy and Strengthening
- General patient group, both residents and workers in Khon Kaen Province, who have confidence in the quality and expertise of the doctors. Most patients or service recipients of the hospital are patients of level x, which are a group with medium to high purchasing power and can pay for medical expenses by themselves.
- Insurance patients or contract patients are a group of contract companies that have agreed to provide discounts for medical treatment or health check-ups (as the case may be). They will be responsible for paying for medical expenses according to the period specified in the contract, including general patients who have the right to claim insurance, which the insurance company has signed a contract with the hospital to be responsible for medical expenses, including according to the Personal Insurance Act.
- Government rights group is a group of patients for whom the company makes a claim directly according to the rights of the patient and the service recipient. Some items that can be claimed include the Comptroller General's Department in the case of advance surgery projects, artificial kidney dialysis from both the government and social security groups, Section 7 patient groups, etc.
In 2024, divided by income group / patient group / service recipients who used the most services, they were self-pay patients (51.17 percent), life insurance patients (42.79 percent), government officials (4.91 percent), and others (1.13 percent), respectively.
• The Brand Image of Ratchaphruek
The Company is continuously working to enhance its corporate image to raise awareness among the people of Khon Kaen. It has implemented marketing campaigns with a proactive approach, focusing on building the organization’s image while expanding its base of new patients both domestically and internationally. This also includes retaining its existing patient base, comprising general patients and contract patients, by managing patient relationships and organizing regular activities to promote both internal and external marketing. The Company utilizes various communication tools, including printed materials and digital media. Efforts have been made to establish brand recognition for Ratchaphruek among key target groups, including teenagers, working adults, and mothers with children, as these groups are considered potential customers for future healthcare and medical services. This is achieved through diverse activities and marketing communications, as well as expanding communication channels to align with the media consumption behavior of these groups. Examples include promotions through social media, influencers, billboards, and LED signs installed at key locations. In an era where negative news can spread quickly and easily via social media, the Company has appointed a dedicated team to monitor such developments closely. If potentially negative information begins to surface, the Company promptly investigates the cause and takes corrective action to address and clarify the situation to the public as quickly as possible.
• Policy on Improving Treatment Quality
The objective is to develop the hospital’s Centers of Specialty (COS).
The Company focuses on recruiting and developing specialists in various medical fields, incorporating advanced and highly efficient medical technologies, and delivering services through a team of knowledgeable, skilled, and experienced medical professionals.
• Pricing Policy
The Company implements a pricing policy at an appropriate level, aligned with the type and method of treatment. The pricing for various treatments is comparable to competitors within the same market level in the area and remains competitive. For overnight room charges, the Company sets prices based on the market rates of comparable hospitals located in the same or nearby locations. Room rates may vary depending on the amenities provided in the rooms.
In this regard, the hospital group has conducted a study on the feasibility of adjusting the price of nursing services to be equal to other hospitals at the same level because currently, hospitals in the medical group have developed significantly and are well-equipped with various tools and equipment, but the price level is still quite low when compared to other hospitals.
• Distribution and Service Channels
The Company has various distribution and service channels according to patient and service recipient groups, including cash patients, life insurance/contract patients, and government rights patients.
The Company’s distribution channels are divided into online channels and direct services at the hospital. This approach ensures a diverse range of distribution and service options, avoiding over-reliance on any single channel, which could pose significant risks if that channel is disrupted. This strategy reduces the risk of losing customers and helps attract new service users across all age groups, aligning with consumer needs and behaviors. The Company has prioritized expanding its online distribution channels, which are developed in-house, to offer flexibility through various platforms where patients and service users can conveniently access services, review packages, or consider diverse treatment options. This includes scheduling medical appointments appropriately. Examples include telemedicine services, which address changes and the "New Normal" lifestyle, as well as purchasing packages directly on the website, Line, and Facebook Fanpage. In the future, the Company may expand distribution to other online shopping platforms to meet the rapidly evolving demands of consumers.
Industry & Competition (Overall)
• Overview of the Private Hospital Business
The private hospital business is highly competitive, facing rivalry both among private entities at the same level and with public healthcare providers, such as government hospitals and after-hours clinics. Additionally, the intensity of competition has increased due to the ongoing merger strategies of large hospital groups, which provide cost advantages and offer a broader range of services to meet diverse customer needs. Nevertheless, the Company focuses on delivering efficient services and management through specialized medical personnel and modern medical equipment, all while maintaining reasonable service fees. Ratchaphruek Hospital has achieved its first JCI (The Joint Commission International) accreditation under Edition 7, reflecting international safety and quality standards in service delivery. The hospital is also well-prepared to accommodate international patients, particularly those from ASEAN, China, Japan, and Laos. The Company has currently planned marketing strategies, service quality development, and personnel enhancement to support these target groups. The focus is on person-centered care, providing seamless services before, during, and after treatment, with reasonable service fees for all patients.
• Estimated Number of Competitors and Company Size
The growth potential for healthcare facilities in Khon Kaen Province and nearby areas is considered significant for the hospital business. This is due to the region's relatively large population and its status as the educational hub of Northeastern Thailand, with Khon Kaen University as a major institution. The area attracts a substantial number of educators and students who live and work there permanently, coupled with a continuous population growth rate. These factors make the region an attractive market for private hospitals. As a result, competition for market share in the hospital business in this area is expected to intensify steadily.
• Competitive Potential Capability in Medical Services
The Company remains committed to providing high-quality medical services at reasonable and cost-effective rates (Value for Money Services). This is supported by a team of skilled and knowledgeable medical professionals, modern and advanced medical equipment, and ongoing development and improvement of work processes and service efficiency. These efforts have led to the hospital receiving international healthcare accreditation from JCI.
• Service Strengths / Despite the intense competition in the private hospital sector, Including the need to compete with public hospitals and medical schools,
the Company emphasizes fair business practices by offering reasonable service fees without unnecessary price competition. Nevertheless, the Company has successfully maintained its position as the leading private hospital in Khon Kaen Province for many years.
This achievement reflects the trust and confidence of patients and service users in Khon Kaen and nearby areas. The hospital focuses on excellence in the following areas:
o Providing professional care and services (Professional)
o Offering treatment with a dedicated team of doctors, nurses, and a multi-disciplinary team (Multi-Disciplinary Team) o Delivering treatments with quality and high standards (Quality)
o Adhering to international standards in medical care. The Joint Commission International (JCI) from the United States is responsible for evaluating quality and safety standards. The Company prioritizes the safety of patients and individuals above all else.
As such, it has established medical quality policies and operational guidelines in compliance with international standards (JCI). This practice aims to enable medical personnel to develop and improve their capabilities in patient care and treatment while reducing the risks associated with complaints regarding patient safety. These complaints often stem from services and operations.
• Characteristics of service recipients and target groups
- The company's main service recipients can be classified into the following main groups: Cash service recipients, accounting for approximately 42.79 percent of revenue from hospital operations in 2024
- Contract service recipients and insurance companies, accounting for approximately 51.17 percent of revenue from hospital operations in 2024 Government sector and service recipients under the Road Accident Victims Protection Act
- For 2024, revenue from government sector and service recipients under the Road Accident Victims Protection Act accounted for 4.91 percent of revenue from hospital operations in 2024
Procurement of Products & Services
Reporting Mode
3117
Procurement (Overall)
• Procurement of Medical and Nursing Teams
The Company has a policy to recruit specialized doctors in various fields, as well as other medical personnel such as nurses, medical technicians, and physical therapists, to ensure comprehensive and high-quality patient care. Over time, the Company has consistently recruited skilled medical professionals and implemented policies to retain them by offering fair compensation and benefits, fostering a positive work environment, and supporting regular medical conferences and training sessions for doctors, nurses, and other medical staff. This ensures that their medical knowledge remains up-to-date, and that patient safety and service quality are maintained.
• Procurement of Medicines and Medical Supplies
Medicines and medical supplies are critical raw materials for hospital operations. The Company emphasizes stringent processes, starting from procurement, which involves a selection committee comprising doctors, pharmacists, the purchasing department, and the accounting department. This committee ensures appropriate procurement and effective inventory management, evaluating factors such as price, efficiency, and quality to meet demand. Almost all medicines and medical supplies are sourced domestically, minimizing the risk of shortages
The Company does not rely on any single supplier for over 30% of its total medicine and medical supply purchases between 2018 and 2024. Additionally, there are no commitments to purchasing more than 30% from any single supplier in the future.
• Medical Equipment and Devices
Currently, the increasing complexity of diseases necessitates the use of modern medical equipment to provide adequate and high-quality patient care. The Company recognizes the growing complexity of diseases and the critical need for advanced medical tools. Although such investments are relatively high, the Company carefully evaluates the necessity and quality of this equipment to ensure it is sufficient and meets demand.
The Company procures medical equipment and devices through distributors in Thailand, with clearly defined pricing agreements and after-sales service terms to maximize value and utility. Modern, efficient, and standardized medical equipment is a critical factor in enhancing the quality of patient care. Recognizing this importance, the Company ensures that medical teams in various fields closely monitor advancements in medical technology.
Additionally, the Company selects only reputable manufacturers and distributors, choosing high-quality equipment at reasonable prices with reliable after-sales support.
Raw Material Acquisition (Overall)
• The procurement of raw materials and suppliers, including medicines, medical supplies, and consumables used in medical treatments, is entirely sourced from domestic manufacturers or distributors. A dedicated committee is assigned to evaluate and approve the introduction of these materials for use in the hospital.
• Transparent Procurement Practices To ensure transparency in the procurement process,
Ratchaphruek Hospital Public Company Limited has established policies to build trust and integrity among stakeholders. Effective supply chain management is recognized as a key factor in achieving sustainable business success. The procurement process includes a comparative evaluation to select quality partners and suppliers. The Company is committed to conducting business under the principles of good corporate governance, guided by ethics and honesty. All suppliers are required to adhere to the Supplier Code of Conduct.
So, The Board of Directors treats suppliers with fairness and mutual benefit, guided by the following policies and practices:
1) A supplier selection system ensures compliance with laws, adherence to safety and occupational health standards, and environmental friendliness. Suppliers are treated based on fair competition, equality, and mutual respect.
2) Confidentiality of supplier information is maintained and not misused for personal or related parties' benefit.
3) Positive relationships and mutual understanding are fostered, with knowledge exchange to co-develop and enhance the value of products and services for mutual growth.
4) Trade agreements are honored, and accurate information is provided. In cases where obligations cannot be met, negotiations with suppliers are initiated in advance to find solutions and prevent damage.
5) The Company does not request, accept, or agree to receive any assets or benefits beyond trade agreements. The supplier selection and evaluation process includes a monitoring system through an Approved Vendor List, using preliminary questionnaires and follow-up inspections to ensure selected suppliers are capable and reliable. Annual evaluations are conducted to ensure ongoing supplier performance.
Production Policy (Overall)
The utilization rate of the patient group is assessed from the actual number of services compared to the maximum service potential, divided into outpatient and inpatient groups. In 2022-2024, the outpatient group had a utilization rate of 33.24 percent, 23.99 percent, and 22.55 percent, respectively. However, the examination room utilization rate is not high because the area is prepared for future services. Meanwhile, the inpatient group had a utilization rate (bed occupancy rate) of 58.29 percent, 68.84 percent, and 62.42 percent, respectively, in 2022-2024. This is due to the opening of the current hospital building, which has an increased number of inpatient rooms.
• Outpatient services (OPD)
- Number of examination rooms (average) 36 examination rooms, 366 days of service
- Maximum outpatient capacity 711,504 times **
- Actual outpatient treatment 160,440 times
- Service utilization rate 22.55 percent
Remarks : ** The maximum outpatient capacity is approximately 54 times per room per day.
• Inpatient Group Services (IPD)
Inpatient Group (IPD) 2024, the number of beds actually used (average) 183 beds, 366 days
- Maximum inpatient capacity 66,978 beds
- The number of inpatients actually treated 41,808 beds
- Service utilization rate 62.42 percent
- Average total service utilization rate 62.42 percent
The service utilization rate of patient groups is assessed from the actual number of services compared to the maximum service potential, divided into outpatient and inpatient groups. In 2022-2024, the outpatient group had a service utilization rate of 33.24 percent, 23.99 percent, and 22.55 percent, respectively, while the inpatient group had a service utilization rate (bed occupancy rate) of 58.29 percent, 68.84 percent, and 62.42 percent in 2022-2024.
Distributors (Overall)
In 2024, the top 3 distributors that the company has contacted to trade are:
1) Zuellig Pharma Co., Ltd. Purchase value of 58,452,276.95 baht
2) DKSH (Thailand) Co., Ltd. Purchase value of 39,462,660.20 baht
3) Dimentic Co., Ltd. Purchase value of 7,682,541.19 baht
Number of Raw-Material Distributors (Overall)
3
Production Capacity (Overall)
| Item | Unit | Unit (if Other) | Used | Capacity |
|---|---|---|---|---|
| Number of outpatients (OPD) (actual treatment) | Others | times | 22.55 | 160,440 |
| Maximum outpatient capacity | Others | times | 0 | 711,504 |
| Number of inpatients (IPD) (actual treatment) | Others | Beds | 62.42 | 41,808 |
| Maximum inpatient capacity (beds) | Others | Beds | 0 | 66,978 |
Domestic/Overseas Purchase Proportion (Overall)
| Raw Material | Source Country | Value |
|---|---|---|
| Medicine and medical supplies | Thailand | 172,087,797.44 |
| Equipment | Thailand | 5,063,597.6 |
Nature of Business — Overview
Introduction
Ratchaphruek Hospital is located in Khon Kaen Province in Northeastern Thailand. Established in 1994 as a private general hospital with 50 beds, it has since grown into a "Healing Environment Hospital" with 198 beds by 2018.
Our vision is to provide high-quality medical services that meet international standards, with a human touch. We see our patients as patients, not customers, as we are not merchants. Similarly, we view our doctors as healthcare providers, not as service sellers. Every staff member is a "giver" of care, united by a common goal that aligns with our core organizational value: "Happiness from Giving." Stability, a critical factor for sustainable growth, stems from strength and flexibility. This strength is rooted in academic excellence, comprising four key areas: quality care, safety, positive patient experiences, and human-centered care. As a private hospital,
We must balance profitability with purpose, preserving the essence of our hospital's mission and the spirit of the medical profession. This involves achieving reasonable profits, not maximizing them at all costs.We are a hospital that fosters a healing environment, offers fair pricing to the community, and maintains international standards in medical treatment and human-centered care.
Product Information — Overview
Introduction
Initially, Ratchaphruek Hospital Public Company Limited operated as a private hospital providing secondary care (low-complexity care), offering diagnostic and treatment services as well as consultations to patients within Khon Kaen Province. Adhering to the motto “Warm as Home, Care by Expertise, Remedy by Heart”
Projects Under Construction
Has Projects Under Construction (Y/N)
No
Introduction
In 2024, the Company has no work that has not yet been delivered.
Debentures & Bills of Exchange
Has Debentures (Y/N)
No
Convertible Securities
Has Convertible Securities (Y/N)
No

